LP(A) MEASUREMENT IN PRIMARY PREVENTION POPULATION MAY LEAD TO INCREASED UTILIZATION OF STATIN THERAPY, A REAL-WORLD EXPERIENCE

Abstract

Therapeutic Area: ASCVD/CVD Risk Reduction Background: Lp(a) is an important independent risk factor for ASCVD, and Lp(a) lowering therapies are in development. We evaluated Lp(a) trends to review impact of Lp(a) testing on utilization of lipid lowering therapies. Methods: Lp(a) is an important independent risk factor for ASCVD, and Lp(a) lowering therapies are in development. We evaluated Lp(a) trends to review impact of Lp(a) testing on utilization of lipid lowering therapies. Results: A total of 3,254 patients (pts) without a history of CAD, stroke, or PAD were identified. Pt characteristics are shown in Table 1. Lp(a) was elevated in 32.9% of tests (mild: 9.6%, moderate: 15.2%, severe: 8.1%). Lp(a) assessment was associated with increased statin therapy use (from 417 to 1271; Tables 3 and 4) and Lp(a) testing (Table 2). While relative percent use of moderate intensity statin did not change, there was less use of low intensity and increase use of high intensity statin. Conclusions: In our large healthcare system, Lp(a) testing in a primary prevention population was associated with increased statin therapy and relative decrease in low- but increase in high-intensity statin. Lp(a) elevation is common, i.e., in 1/3 of pts tested, with moderate-severe in 1/6. Given the relative common finding of elevation and familial nature, widespread testing may identify more individuals eligible for lipid lowering therapy.